Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerAbdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, peritoneal neoplasmActive, not recruitingPhase 32026-09-25NCT05257408

2 results · Page 1 of 1

Swipe the table sideways for more columns.

116 results · Page 1 of 5

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Site 001São PauloBrazil1
Site 009AtlantaUnited States1
Site 014San FranciscoUnited States1
Site 032AuroraUnited States1
Site 042WestonUnited States1
Site 049PortlandUnited States1
Site 055LondonUnited Kingdom1
Site 080JerusalemIsrael1
Site 108LeuvenBelgium1
Site 109BrusselsBelgium1
Site 117TorontoCanada1
Site 121MilwaukeeUnited States1
Site 122MilanItaly1
Site 124RomeItaly1
Site 127PittsburghUnited States1
Site 128BostonUnited States1
Site 150Palo AltoUnited States1
Site 161RomaItaly1
Site 200Overland ParkUnited States1
Site 203Tel AvivIsrael1
Site 229AustinUnited States1
Site 272AtlantaUnited States1
Site 273MontrealCanada1
Site 275FlushingUnited States1
Site 276Rapid CityUnited States1